PROG Holdings: SK Life Science Unveils Groundbreaking Epilepsy Data at AAN 2025
- SK Life Science will present pivotal data on XCOPRI® at AAN 2025 to demonstrate its efficacy in managing epilepsy.
- A comprehensive study shows significant reduction in seizure activity with cenobamate treatment for patients with uncontrolled seizures.
- SK Life Science emphasizes ongoing research to enhance epilepsy treatment strategies and improve patient outcomes with cenobamate.
Advancements in Epilepsy Management: SK Life Science Prepares for AAN 2025
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals and a prominent player in the development of treatments for central nervous system disorders, is set to present pivotal data on XCOPRI® (cenobamate tablets) at the upcoming 77th American Academy of Neurology (AAN) Annual Meeting in San Diego from April 5-9, 2025. This presentation is expected to substantiate the clinical and real-world evidence underscoring cenobamate's efficacy in managing epilepsy, particularly in reducing seizure activity. Louis Ferrari, Vice President of Medical Affairs at SK Life Science, highlights the company’s dedication to advancing seizure management and notes that the achievement of seizure freedom remains a vital objective for many patients.
The data to be presented includes findings from a comprehensive retrospective multicenter observational study that involves 37 patients suffering from uncontrolled seizures. This 24-week study reveals a significant reduction in both epileptiform activity and clinically reported seizures during adjunctive treatment with cenobamate. Such findings are essential not only for clinicians but also for patients seeking effective solutions for their condition. Additionally, SK Life Science plans to showcase further data on cenobamate's safety and therapeutic potential across diverse patient populations, reinforcing their commitment to optimizing treatment strategies for epilepsy.
Among the notable presentations scheduled for the meeting is a study on cenobamate's effects on responsive neurostimulation epileptiform events, which will be presented on April 7. Following this, a randomized, double-blind, placebo-controlled study focusing on the efficacy of cenobamate in Asian patients with focal seizures is slated for April 8. Another significant session on early response rates with adjunctive cenobamate in uncontrolled focal seizures will also take place on the same day. These presentations exemplify SK Life Science's ongoing research endeavors aimed at improving outcomes for epilepsy patients and expanding the understanding of cenobamate's role in treatment.
In conjunction with SK Life Science's presentations, the AAN 2025 Annual Meeting will feature a multitude of significant clinical findings from NYU Langone's Department of Neurology. Experts will discuss various topics, including optimal blood pressure management in acute hemorrhagic stroke and the implications of social determinants of health on pediatric multiple sclerosis. This convergence of neurological expertise at AAN underscores a broader commitment within the medical community to enhance patient care and drive innovation across neurological disorders.